Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Peter Gale

Showing results (181-190 of 373) with videos related to

Pageof 38
Sort By:
Biomedicines|January 8, 2025
Acute Myeloid Leukemia with Normal Cytogenetics and <i>NPM1</i>-Mutation: Impact of Mutation Topography on OutcomesMingyue Zhao, Mingyue Liao, Robert Peter Gale, et al.
Leukemia Research|June 11, 2016
BCL11A expression in acute phase chronic myeloid leukemiaJiawei Yin, Fan Zhang, Huiquan Tao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 8, 2009
High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcomaPatrick J Stiff, Manza-A Agovi, Karen H Antman, et al.
The Oncologist|June 28, 2025
Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United StatesYuting Yan, Yin Liu, Tonglu Qiu, et al.
Stem Cell Investigation|October 26, 2016
<i>TET2</i> mutations were predictive of inferior prognosis in the presence of <i>ASXL1</i> mutations in patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
British Journal of Haematology|December 28, 2022
Impact of the International Consensus Classification of myelodysplastic syndromesYudi Zhang, Junying Wu, Zefeng Xu, et al.
Experimental Hematology & Oncology|October 17, 2022
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromesJunying Wu, Yudi Zhang, Tiejun Qin, et al.
Experimental Hematology & Oncology|May 29, 2015
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Blood Cancer Journal|November 24, 2025
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosisMonia Marchetti, Alessandro Maria Vannucchi, John O Mascarenhas, et al.
Experimental Hematology & Oncology|April 30, 2016
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromesGege Feng, Robert Peter Gale, Wen Cui, et al.
Pageof 38

Showing results (181-190 of 373) with videos related to

Sort By:
Pageof 38
Biomedicines|January 8, 2025
Acute Myeloid Leukemia with Normal Cytogenetics and <i>NPM1</i>-Mutation: Impact of Mutation Topography on OutcomesMingyue Zhao, Mingyue Liao, Robert Peter Gale, et al.
Leukemia Research|June 11, 2016
BCL11A expression in acute phase chronic myeloid leukemiaJiawei Yin, Fan Zhang, Huiquan Tao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 8, 2009
High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcomaPatrick J Stiff, Manza-A Agovi, Karen H Antman, et al.
The Oncologist|June 28, 2025
Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United StatesYuting Yan, Yin Liu, Tonglu Qiu, et al.
Stem Cell Investigation|October 26, 2016
<i>TET2</i> mutations were predictive of inferior prognosis in the presence of <i>ASXL1</i> mutations in patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
British Journal of Haematology|December 28, 2022
Impact of the International Consensus Classification of myelodysplastic syndromesYudi Zhang, Junying Wu, Zefeng Xu, et al.
Experimental Hematology & Oncology|October 17, 2022
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromesJunying Wu, Yudi Zhang, Tiejun Qin, et al.
Experimental Hematology & Oncology|May 29, 2015
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Blood Cancer Journal|November 24, 2025
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosisMonia Marchetti, Alessandro Maria Vannucchi, John O Mascarenhas, et al.
Experimental Hematology & Oncology|April 30, 2016
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromesGege Feng, Robert Peter Gale, Wen Cui, et al.
Pageof 38